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Duchennemuscular dystrophy is a devastatingmusclewasting disease for which there is no effective
treatment. In this issue of Cell Stem Cell, Benchaouir et al. (2007) demonstrate the delivery of genet-
ically correctedCD133+ patient cells intomice, suggesting a newpotential avenue for autologous cell
therapy.Duchenne muscular dystrophy (DMD)
is a progressive muscle wasting dis-
ease resulting from the absence of
the 420 kDa cytoskelelal dystrophin
protein. Patients are wheelchair bound
by their early teens, develop heart
problems, and may live into their
twenties with appropriate respiratory
support. Various strategies to replace
the defective dystrophin protein are
being tested (Muntoni and Wells,
2007; Cossu and Sampaolesi, 2007).
One approach is transplantation of
muscle precursor cells (myoblasts)
that can produce the dystrophin pro-
tein. Myoblasts normally arise from
satellite cells (on the surface of mature
myofibers) that are closely associated
with the microvasculature (Christov
et al., 2007). The extent to which vari-
ous stem cells can contribute to satel-
lite cell and myoblast populations is
a topic of intense interest. Clinical trials
revealed that transplanted human
myoblasts were lost rapidly and so
were disappointing (Boldrin and Mor-
gan, 2007). Alternative stem cells with
myogenic potential ideally need to be
derived from the patient’s own cells to
avoid immunorejection, and this might
be possible using autologous stem
cell populations isolated from a variety
of adult tissues (Boldrin and Morgan,
2007; Peault et al., 2007). In this issue
of Cell Stem Cell, Benchaouir et al.
(2007) utilize the mdx mouse model of
DMD to provide a proof of principle
that human progenitor cells isolated
from DMD blood and muscle biopsies
can be genetically altered and then
transplanted to correct the genetic
deficiency of dystrophic muscle.Circulating human CD133+ (also
known as AC133+) cells exhibit limited
in vitro proliferation and require cocul-
ture for myogenic fusion, but in vivo
have been shown to contribute to the
repair of both dystrophic muscles
and endothelial cells after intra-arterial
or intramuscular injection into im-
munocompromised scid/mdx mice
(Torrente et al., 2004). In contrast, the
present study observes excellent
in vitro proliferative and inherent myo-
genic capacity of normal and DMD
muscle-derived human CD133+ cells
obtained by cell sorting from enzy-
matically dissociated muscle biopsies.
The authors genetically transformed
both blood- and muscle-derived
CD133+ cells from DMD boys for use
in key in vivo experiments. The isolated
human cells were transduced with a
lentiviral vector containing the U7
RNA to induce exon 51 skipping. Skip-
ping this exon places the mRNA back
in frame so that a truncated, but func-
tional, dystrophin protein missing only
exon 51 is transcribed (Yokata et al.,
2007). The exon skipping therapeutic
approach is applicable to gene defects
of up to 70% of DMD patients, and
avoids the problems associated with
delivery of the prohibitively large full-
length dystrophin gene or a (less func-
tional) truncated minigene.
Intensive research is currently fo-
cused on delivering antisense oligo-
nucleotides directly into DMD boys to
induce skipping of the endogenous
exon 51, thereby restoring expression
of functional dystrophin. Indeed, two
clinical trials involving intramuscular
injections are already in progressCell Stem Cell 1,(Yokata et al., 2007). Ex vivo viral
transduction of autologous CD133+
cells is an alternative strategy to yield
functional (exon-skipped) dystrophin+
cells for implantation into the original
DMD patient. This approach avoids
the major issue of immunological re-
jection that would occur following
transplantation of heterologous nor-
mal donor (dystrophin+) myogenic
cells. In the study by Benchaouir
et al., it is not clear for how long the
different CD133+ DMD cells were cul-
tured prior to transduction with the U7
exon 51 lentivirus vector. The trans-
duced human cells were transplanted
after 24 hr into the right tibialis ante-
rior muscle or the femoral artery of
scid/mdx mice. These dystrophic scid
host mice, which accept xenografts,
were subjected to exercise 1 day prior
to transplantation to increase muscle
damage. By 3 weeks, the implanted
cells gave rise to myofibers express-
ing the truncated human dystrophin
and improved muscle function. This
experiment is considered a prelude
for transplantation of such genetically
corrected autologous CD133+ cells
back into a DMD patient.
The genetic modification of adult
stem cell populations harvested from
patients to produce dystrophin is not
new. Cossu and colleagues have
shown that modified mesoangioblasts
derived from the walls of blood vessels
(of mice and humans) produce dystro-
phin-positivemyofibers in the scid/mdx
mouse and in the dog model of DMD
(Cossu and Sampaolesi, 2007). The
relationship between mesangioblasts
(possibly equivalent to pericytes) andDecember 2007 ª2007 Elsevier Inc. 595
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in the present study is not clear.
CD133+ cells are considered to be
hematopoietic/endothelial stem cells
of bone marrow origin that can give
rise to both endothelial cells and
myoblasts (Peault et al., 2007). Both
mesangioblasts and CD133+ cells
manifest a strong myogenic potential
in vivo that can be enhanced by injury.
These populations also share the ad-
vantage of being delivered via the
bloodstream, and are more effective
than stem cells extracted from bone
marrow (Peault et al., 2007). Relevant
to the crucial aspect of systemic deliv-
ery of such myogenic stem cells is the
observation that intra-arterial delivery
of lentivirus-transduced skeletal mus-
cle side-population (SP) stem cells in-
creases their myogenic contribution
compared with intravenous injection,
raising concerns about the likely effi-
cacy of total systemic distribution to
all muscles (Bachrach et al., 2006).
There is little doubt that it is possible
to isolate populations of stem cells
with the potential to repair damaged
muscle and replenish the satellite cell
pool, although the extent to which
this occurs is debated. In a recent dou-
ble-blind phase I clinical trial, auto-
logous CD133+ cells extracted from
(1 g) muscle biopsies were trans-
planted by intramuscular injection
into eight boys with DMD and sampled
after 7 months (Torrente et al., 2007).
These cells were not genetically cor-
rected, their fate was not monitored,
and the boys were not immunosup-
pressed, because the trial was de-
signed only to test the safety of these
implanted cells (grown for only 48 hr
in culture). No adverse effects were re-596 Cell Stem Cell 1, December 2007 ª2ported, although the extent to which
these cells survived is not known. In-
creasing the efficiency of delivery of
these cells, via the blood if possible,
and targeting cardiac muscle remain
major challenges.
The proof of principle experiments
described by Benchaouir et al. in this
issue show that steady progress is be-
ing made toward the goal of stem cell-
mediated restoration of dystrophin
expression. This approach involves
substantial tissue culture and so may
result in high costs that limit the num-
ber of patients who can be treated.
Beyond possible safety aspects of
stem cell therapy (Boldrin andMorgan,
2007), various issues remain to be
clarified, including the following: the
potential to enhance proliferation of
blood-derived CD133+ cells in culture
(and storage for repeated treatments);
the time required in culture for autolo-
gous cells prior to implantation back
into the patient; the patient age and as-
sociated muscle environment that the
transplanted cells will encounter; the
relative efficiency of blood- compared
withmuscle-derived cells to contribute
muscle nuclei; the best route of deliv-
ery; and the longevity of the trans-
planted muscle nuclei in vivo (with no
immunosuppression), in particular the
extent to which they engraft the satel-
lite cell compartment and thus provide
a renewable source of genetically cor-
rected stem cells within muscle. The
anticipated requirement for repeated
treatment cycles using this method
underscores the value of blood-
derived CD133+ autologous cells,
compared with the need for frequent
biopsies of the dystrophic muscles,
and is of central importance when007 Elsevier Inc.considering such a clinical therapy.
The promising developments repre-
sented by these new sources of
systemically delivered myogenic cells
maintain the hope for DMD patients
and their families for future autologous
stem cell therapies.
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